Clinical Trial Update: Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration [Phase 3]

View source ↗

Summary

A Phase 3 safety and efficacy trial comparing Biocad's BCD-021 to Lucentis for wet age-related macular degeneration has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• BCD-021
• Lucentis (ranibizumab)

Snippet

Sponsor: Biocad | Conditions: Wet Age-related Macular Degeneration | Phase 3 | Status: WITHDRAWN